Evaluation of safety and efficacy of eribulin for patients advanced or recurrent HER2 negative breast cancer who have been treated with anthracyclines and taxanes
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000007121
- Lead Sponsor
- Kyushu Breast Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 50
Not provided
1 ineligible patients complicated with infectious diseases or who suspected infectious diseases with fever 2. diarrheal , ileus 3. GI bleeding 4.severe drug allergy 5. severe renal and/ or liver dysfunction 6.significant interstitial pneumonia or pulmonary fibrosis by chest radiograph 7.pleural effusion, peritoneal effusion 8.poorly controlled hypertension or diabetes mellitus 9.maintenance therapy with systemic corticosteroids 10.pregnant women or women with suspected pregnancy 11.patients who received blood transfusion, blood products or G-CSF within 7 days prior to this study 12.presence of the active other malignancies 13.severe psychiatric disorder 14 brain metastases 15.patients judged by the investigator to be unfit for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall response rate
- Secondary Outcome Measures
Name Time Method duration of response progression- free survival overall survival